Completed PHASE2 INTERVENTIONAL 4-arm NCT01826916

EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema

EDEMA2: An Open-Label Study to Assess the Efficacy and Tolerability of Repeated Doses of DX-88 (Recombinant Plasma Kallikrein Inhibitor) in Patients With Hereditary Angioedema

Sponsor: Shire

Conditions Hereditary Angioedema (HAE)

Interventions DX-88 (ecallantide)

Updated 8 times since 2017 Last updated: May 14, 2021 Started: Nov 1, 2003 Primary completion: Dec 1, 2005 Completion: Jan 1, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Hereditary Angioedema (HAE) and is currently completed. Shire leads this study, which shows 8 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jun 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Jun 2021 [monthly]

Completed PHASE2
Dec 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Dec 2018 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shire

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.